New Investigational Clinical Data for Ipsen\'s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting

New Investigational Clinical Data for Ipsen's Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting

01:01 EDT 24 May 2019 | FinanzNachrichten

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx), liposomal irinotecan (O...

More From BioPortfolio on "New Investigational Clinical Data for Ipsen's Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting"